// App-Quantinova.ai

802 ⋆ : An Ongoing Extension of a Phase 2 Study of WTX101 in Newly Diagnosed Wilson Disease Patients

Researchers

Presenter

  • Michael L. Schilskv

Principal Investigators

  • Frederick K. Askari

  • Peter Ferenci

  • Aftab Ala

  • Anna Czlonkowska

  • David J. Nicholl

  • Jeffrey Bronstein

  • Danny Bega

  • Karl Heinz Weiss

Medical Centers

  • Medicine and Surgery, Yale University Medical Center, New Haven, CT

  • Department of Internal Medicine, University of Michigan, Ann Arbor, MI

  • Medical University of Vienna, Vienna, Austria

  • Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom

  • Institute of Psychiatry and Neurology Warsaw, Warsaw, Poland

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • University of California, Los Angeles, Los Angeles, CA

  • Northwestern University, Chicago, IL

  • Medical School, University of Heidelberg, Heidelberg, Germany

Locations

  • United States

  • Austria

  • United Kingdom

  • Poland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Wilson disease

Biomarkers

  • Human albumin

Drug/Treatment

  • Tetrathiomolybdate

  • WTX 101

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved